Earlier Age at Menarche Raises Type 2 Diabetes Risk
By Lori Solomon HealthDay Reporter
WEDNESDAY, Dec. 6, 2023 -- Earlier age at menarche is associated with type 2 diabetes risk among women younger than 65 years, according to a study published online Dec. 5 in BMJ Nutrition Prevention & Health.
Maria P. Santos, from the Tulane University School of Public Health and Tropical Medicine in New Orleans, and colleagues used data from 17,377 women (aged 20 to 65 years) participating in the National Health and Nutrition Examination Survey (1999 to 2018) to examine associations of age at menarche with type 2 diabetes and with cardiovascular disease (CVD) complications among women with diabetes.
The researchers found that 10.2 percent of women reported having type 2 diabetes. When adjusting for age, race/ethnicity, education, parity, menopause status, family history of diabetes, smoking status, physical activity, alcohol consumption, and body mass index, there was an association seen between earlier age at menarche and type 2 diabetes compared with a median age at menarche of 13 years. Earlier age at menarche among women with diabetes, was associated with stroke, but not with total CVD, in an adjusted analysis. Similarly, extremely early age at menarche (10 years and younger) was significantly associated with stroke (adjusted odds ratio, 2.66).
"These findings support the possibility that age at menarche may be incorporated into early-life strategies for preventing diabetes and progression of diabetes complications," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer
TUESDAY, May 28, 2024 -- Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.